Expert Network / Advisory
The Due Diligence Authority: Why Generic Expert Networks Fail in HealthTech M&A
In the high-stakes world of Private Equity, speed and specialized knowledge are paramount. When evaluating a potential Healthcare Technology acquisition, the difference between a successful deal and a costly miss often comes down to the quality of the commercial and technical diligence performed in the first 72 hours.
For too long, deal teams have relied on generalist expert networks (ENs) that prioritize speed-to-match over depth of expertise. In a sector as regulated and complex as HealthTech—where compliance with Stark Law, Anti-Kickback Statutes, and technical debt in EHR/RCM platforms can sink a billion-dollar deal—a generalist approach is a critical vulnerability.
The Contextualized Expert Access You Need
At Chou Group, we don’t offer a generalized database. We offer a Contextualized Expert Network validated by the content on this blog. Every article, market map, and insight piece is built on the proprietary, deep-dive knowledge of our vetted network.
This network is built by current healthcare technology decision makers and for sophisticated investors:
Unmatched Operational Authority
Our expert collective is not drawn from general consulting rosters; they are operational leaders who have run, bought, and operated technology in the healthcare industry.
120+ Years: Our team collectively boasts over 120 years of hands-on experience in healthcare technology leadership. This isn’t theoretical knowledge—it’s experience navigating the messy realities of provider systems, payer-provider workflows, and complex vendor landscapes.
$3B+ Budget Authority: Critically, our experts have overseen over $3 Billion in cumulative IT budget authority. They know where the money is spent, what technologies fail, and which platforms actually deliver ROI in a clinical setting. They can instantly assess the CapEx risk and technical debt of your target company’s platform.
Why Our Specialized Network Wins Against the Generalists
When a PE firm asks a generalist EN for an “EHR expert,” they get a former sales executive or a high-level consultant. When they come to us, they get the former VP of Interoperability for a 50-hospital system or the Chief Revenue Cycle Officer who personally managed a successful transition to value-based care.
Our content provides the pre-diligence blueprint; our experts provide the verdict. This synergy accelerates your deal cycle by giving you validated, investment-grade context before the first expert call even begins.
Accelerate Your HealthTech Due Diligence Today
Stop wasting time interviewing high-level generalists. Suppose you are conducting diligence on a provider-facing SaaS platform, a niche RCM solution, or a disruptive Clinical AI vendor. In that case, you need domain expertise that is both deep and current.
Would you be ready to bypass the generalists?
You can contact us now to gain specialized operational insights that can help de-risk your next HealthTech investment.